TP53 and B-cell chronic lymphocytic leukemia: It is approved since 2014 in combination with rituximab for the treatment of relapsed chronic lymphocytic leukemia (B-CLL) and for first-line therapy of B-CLL with del17p or TP53 mutation and as a monotherapy for refractory follicular lymphoma.